614-487-3695 info@trim-edicine.com
TRIM-edicine TRIM-edicine
  • Home
  • About
  • Leadership
  • Partnership
  • Technology
  • News
  • Contact
  • TRIM-edicne
  • Regenerative medicine and therapy
  • Leading the innovation and development of regenerative medicine

Welcome to TRIM-edicine!

We are a US biotech company focused on restoring cell health and resilience, with profound initial indications for the treatment of cancers and rare diseases, the protection of multiple organ injuries, and the effective reversal of aging.
We are looking for investors, development partners, or licensees. Interested parties please contact us for further information and discussions.

 

Recent News

  • On March 1, 2022, the Center for Drug Evaluation of the State Drug Administration announced that ATAP-M8 was approved by the Center for Drug Evaluation of the State Drug Administration (hereinafter referred to as CDE) to officially enter human clinical trials and carry out Clinical trials in advanced solid tumors. March 15, 2022
  • TRIM-edicine, Inc. was awarded a new Phase II SBIR grant (2019-2022) to advance commercialization efforts of MG53 in the wounding healing application. March 19, 2019
  • Dr. Ma’s group published two additional articles revealing the physiological role and potential translational application of MG53 in corneal injury as well as MG53’s role in preventing valvular heart disease. February 20, 2019
  • Dr. Ma was invited to present at “TEDxColumbus: On The Edge”. (video inside) November 30, 2018
  • TRIM-edicine was awarded a Phase I SBIR grant (2017-2018) for conducting proof-of-concept studies with MG53 in wounding healing application. June 23, 2017

 

Copyright © 2011 TRIM-edicine All Rights Reserved | Terms